The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer

Journal of Urology

Volumn 185, Issue 5, 2011, Pages 1656-1660

  Whitson, Jared M ^a   Porten, Sima P ^a   Hilton, Joan F ^b   Cowan, Janet E ^a   Perez, Nannette ^a   Cooperberg, Matthew R ^a,c   Greene, Kirsten L ^a,c   Meng, Maxwell V ^a,c   Simko, Jeff P ^b,c   Shinohara, Katsuto ^a,c   Carroll, Peter R ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biopsy; prostate; prostate specific antigen; prostatic neoplasms; risk

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER SIZE; CANCER STAGING; COHORT ANALYSIS; DISEASE ASSOCIATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER;

BIOPSY; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953767326     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.12.042     Document Type: Article

References (17)

1. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868
2. M.R. Cooperberg, D.P. Lubeck, and M.V. Meng The changing face of low-risk prostate cancer: trends in clinical presentation and primary management J Clin Oncol 22 2004 2141
3. D.A. Barocas, J.E. Cowan, and J.A. Smith Jr What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database J Urol 180 2008 1330
4. P.R. Carroll Early stage prostate cancerdo we have a problem with over-detection, overtreatment or both? J Urol 173 2005 1061
5. M.A. Dall'Era, B.R. Konety, and J.E. Cowan Active surveillance for the management of prostate cancer in a contemporary cohort Cancer 112 2008 2664
6. H.B. Carter, A. Kettermann, and C. Warlick Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience J Urol 178 2007 2359
7. L. Klotz, L. Zhang, and A. Lam Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126
8. NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, Version 1.2010 National Comprehensive Cancer Network 2009 http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp Accessed September 4, 2010
9. M. Al Otaibi, P. Ross, and N. Fahmy Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance Cancer 113 2008 286
10. M.K. Ng, N. Van As, and K. Thomas Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer PSA velocity vs PSA doubling time BJU Int 103 2009 872
11. M.I. Patel, D.T. DeConcini, and E. Lopez-Corona An analysis of men with clinically localized prostate cancer who deferred definitive therapy J Urol 171 2004 1520
12. A.J. Stephenson, A.G. Aprikian, and L. Souhami Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer Urology 59 2002 652
13. A.E. Ross, S. Loeb, and P. Landis Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program J Clin Oncol 28 2010 2810
14. I.M. Thompson, D.P. Ankerst, and C. Chi Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 2006 529
15. J.M. Whitson, and P.R. Carroll Active surveillance for early-stage prostate cancer: defining the triggers for intervention J Clin Oncol 28 2010 2807
16. J.M. Whitson, and B.R. Konety Should men over the age of 65 years receive PSA screening? Argument in favor Nat Clin Pract Urol 5 2008 230
17. K.S. Tseng, P. Landis, and J.I. Epstein Risk stratification of men choosing surveillance for low risk prostate cancer J Urol 183 2010 1779